1.Treatment pattern of adoptive transfer of immune cells and its application in perioperative period for advanced gastric cancer.
Xiao-hui DU ; Ying-xin XU ; Lin CHEN ; Rong LI
Chinese Journal of Gastrointestinal Surgery 2013;16(1):15-17
Recently immunotherapy for gastrointestinal tumor has rapidly developed, and has improved the effect of cancer comprehensive treatment as an adjunctive therapy in combination with surgery, chemotherapy, and radiation therapy. Adoptive transfer of immune cells is an important treatment method for advanced gastric cancer. In this paper, we reviewed the application of adoptive transfer therapy for advanced gastric cancer in the perioperative period and propose a new model for immunotherapy of advanced gastric cancer based on our experience and the results of clinical experiment.
Humans
;
Immunotherapy, Adoptive
;
methods
;
Perioperative Care
;
Stomach Neoplasms
;
therapy
3.Application of gene therapy in tumor adoptive immunotherapy.
Journal of Biomedical Engineering 2008;25(2):482-486
Adoptive cell transfer of tumor-infiltrating lymphocyte (TIL) has resulted in clear and reproducible responses in a substantial percentage (approximately 50%) of patients with metastatic melanoma. The availability of tumor reactive TIL limits the use of adoptive cell transfer for the treatment of most non-melanoma cancer patients. Recent report indicated that adoptive transfer of T lymphocytes genetically modified with T-cell receptor (TCR) against a tumor antigen resulted in objective response in melanoma patients, thus shedding light on the use of this strategy for the treatment of common epithelial cancers beyond melanoma. In this review, the current status and potential use of genetic modification in the adoptive immunotherapy of cancer patients are be discussed.
Genetic Therapy
;
methods
;
Humans
;
Immunotherapy, Adoptive
;
methods
;
trends
;
Lymphocytes, Tumor-Infiltrating
;
immunology
;
transplantation
;
Neoplasms
;
therapy
4.Research progress of gammadelta T cell-based immunotherapy.
Fu-ming QIU ; Zhong-peng LI ; Jian HUANG
Journal of Zhejiang University. Medical sciences 2010;39(4):424-429
GammadeltaT cells are considered as linkage between innate and adaptive immune response, which recognize specific antigen without MHC-restriction. Vgamma9Vdelta2T cells, isolated from peripheral blood and tumor tissue, can be activated by non-peptide phosphoantigen through binding to its gammadeltaTCR and proliferate under IL-2 stimulation. It has been shown that Vgamma9Vdelta2T cells possess anticancer activity against several types of tumor in vitro, as well as inhibit the growth of lymphoma, breast cancer and malignant melanoma in vivo. The phase I clinical trial of the application of Vgamma9Vdelta2T cells in treatment of lung cancer, renal cancer and prostate cancer demonstrated promising results. This review summarizes the recent advances in antigen recognition and activation of gammadeltaT cells, and the gammadeltaT cell-based immunotherapy for cancer treatment.
Humans
;
Immunotherapy
;
methods
;
Immunotherapy, Adoptive
;
methods
;
Neoplasms
;
immunology
;
therapy
;
Receptors, Antigen, T-Cell, gamma-delta
;
immunology
;
T-Lymphocyte Subsets
;
immunology
5.CAR Technology and Its Application in Treatment of Multiple Myeloma--Review.
Tong LI ; Hong-Tao WANG ; Zhuo-Gang LIU
Journal of Experimental Hematology 2016;24(1):279-284
Multiple myeloma (MM) is a hematologic malignancy resulted from genetic mutations in the process of B lymphocyte differentiating into plasma cells, the chemotherapy is the main treatment method, especially with the development of proteasome inhibitors and other drugs, the overall survival rate of MM patients has improved greatly, but the chemoresistance is still an important reason for treatment failure. Chimeric antigen receptor (CAR)-modified T lymphocyte therapy is a new method for tumor adoptive immunotherapy. By means of genetic modification, T cells are able to identify the target antigen specifically, and to kill target cells without major histocompatibility complex (MHC) restriction, therefore the specific killing activity is conspicuous, which has got considerable attention by the public, and has made remarkable achievements particularly in the treatment of B-lineage leukemia and lymphoma, but no systematic literatures were reported in the field of multiple myeloma using CAR therapy. Therefore, this review summarizes the research results of different CAR target in vivo and in vitro experiments for multiple myeloma.
Genetic Therapy
;
Humans
;
Immunotherapy, Adoptive
;
methods
;
Multiple Myeloma
;
therapy
;
Receptors, Antigen, T-Cell
;
T-Lymphocytes
;
cytology
6.Progress in Research and Application of CAR-T Cell Therapy in T-Lymphocyte Tumors --Review.
Journal of Experimental Hematology 2023;31(6):1894-1898
T-lymphocyte tumors are a group of diseases containing various types of lymphatic system tumors, with strong heterogeneity and poor clinical outcomes. Chimeric antigen receptor T (CAR-T) cell therapy, as a new immune cell therapy, has made a breakthrough in the field of B-lymphocyte tumors. People are interested in the application prospect of this technique in the field of T-lymphocyte tumors. Some studies have shown that CAR-T cell therapy has made some progress in the treatment of T-lymphocyte tumors, and CAR-T for some targets has entered the stage of clinical trials. However, due to the characteristics of T cells, there are also many challenges. This article reviews the research and application of CAR-T cell therapy in T-lymphocyte tumors.
Humans
;
T-Lymphocytes
;
Receptors, Chimeric Antigen/metabolism*
;
Neoplasms/metabolism*
;
Immunotherapy, Adoptive/methods*
;
Cell- and Tissue-Based Therapy
7.Progress in clinical studies of chimeric antigen receptor engineered T cells for treatment of childhood cancer.
Ya-Ru NI ; Xiao-Jun XU ; Yong-Min TANG
Chinese Journal of Contemporary Pediatrics 2017;19(11):1219-1224
Nowadays, the 5-year survival rate of childhood cancer patients can be more than 80%, but some patients with relapse and refractory cancers have shown no good response to traditional strategies. Chimeric antigen receptor engineered T (CAR-T) cell therapy is promising for these patients. CAR-T cells recognize the tumor-associated antigens in a non-major histocompatibility complex-restricted manner, so their anti-tumor ability is enhanced. There are four generations of CAR-T cells now. The complete remission rate of pediatric patients with relapse and refractory acute lymphoblastic leukemia can be as high as 90% when treated with CD19-targeting CAR-T cells. Furthermore, CAR-T cell therapy can also be used to bridge to transplantation and donor CAR-T cell infusion can be a strategy to prevent relapse after hematopoietic stem cell transplantation. As to solid tumors, only patients with neuroblastoma present good response to the GD2-targeting CAR-T cell therapy. The toxic or side effects of CAR-T cell therapy include cytokine release syndrome, off-tumor effect, tumor lysis syndrome, and insertion mutation. Although the CD19-targeting CAR-T cell therapy for childhood cancer can result in a high remission rate, the relapse rate is high, including CD19and CD19relapse. The mechanisms for relapse merit further investigatio.
Antigens, CD19
;
immunology
;
Child
;
Humans
;
Immunotherapy, Adoptive
;
adverse effects
;
methods
;
Neoplasms
;
therapy
;
Receptors, Antigen, T-Cell
;
genetics
;
T-Lymphocytes
;
transplantation
8.Effector cells derived from naive T cells used in tumor immunotherapy of mice bearing B16 melanoma.
Ming WEN ; Weili XU ; Lili REN ; Fei GAO ; Naipeng CUI ; Junye WEN ; Xinjiang LI ; Lin LIN ; Zhenfeng MA ; Baoping CHEN ; Jianhui CAI ;
Chinese Medical Journal 2014;127(7):1328-1333
BACKGROUNDAdoptive cell transfer (ACT) immunotherapy has been used clinically for years to treat malignancies. Improving the killing efficiency of effector cells, such as tumor-specific cytotoxic T lymphocytes (CTLs), is an important component for enhancing the clinical response of cancer immunotherapy. Hence, we explored a novel method for preparing cancer-specific CTLs using naive T lymphocytes.
METHODSC57BL/6 mice bearing B16 melanoma tumors were pretreated with cyclophosphamide (CTX) by peritoneal injection. The immunosuppressive influence of CTX on tumor regression and the tumor microenvironment was assessed. Naive T cells and T cell pools were isolated via negative selection using immunomagnetic beads. The proliferative potential and cytokine production of different T cell subpopulations were evaluated in vitro. Tumor-specific CTLs derived from naive T cells (naive CD4+ T cells: naive CD8+ T cells = 2:1) and pooled T cells were generated in vitro, respectively. B16 melanoma-bearing C57BL/6 mice were pretreated with CTX, followed by ACT immunotherapy using dendritic cell-induced CTLs. The homing abilities of the effector cells and interleukin-2 (IL-2), interferon-γ, granzyme B, and perforin mRNA levels in tumor tissues were evaluated, and the change in tumor volume was measured.
RESULTSMice receiving CTX peritoneal pretreatment injections did not display tumor regression compared with control mice. However, a significant downregulation of splenic Tregs and tumor growth factor-β1 (TGF-β1) and interleukin-10 (IL-10) serum levels was observed (P < 0.05). Naive T cells showed a stronger proliferative capacity and elevated cytokine production than did pooled T cells (P < 0.05). In addition, effector cells generated from naive T cells displayed more potent antitumor activity in vivo than those derived from pooled T cells (P < 0.05).
CONCLUSIONEffector cells derived from the naive T cells possess a stronger proliferative potential, homing capacity, and enhanced cytokine production, which leads to a superior antitumor response.
Animals ; Cell Line, Tumor ; Cells, Cultured ; Female ; Flow Cytometry ; Immunotherapy, Adoptive ; methods ; Melanoma, Experimental ; therapy ; Mice, Inbred C57BL
9.Preparation of CD52-targeted chimeric antigen receptor-modified T cells and their anti-leukemia effects.
Yan LIU ; Yu LIU ; Ke Jing TANG ; Zhao Qi CHEN ; Jun Li MOU ; Ying Xi XU ; Hai Yan XING ; Zheng TIAN ; Qing RAO ; Min WANG ; Jian Xiang WANG
Chinese Journal of Hematology 2022;43(4):279-286
Objective: To construct chimeric antigen receptor (CAR) T cells targeting CD52 (CD52 CAR-T) and validate the effect of CD52 CAR-T cells on CD52-positive leukemia. Methods: A second-generation CD52-targeting CAR bearing 4-1BB costimulatory domain was ligated into a lentiviral vector through molecular cloning. Lentivirus was prepared and packaged by 293 T cells with a four-plasmid system. Fluorescein was used to label cell surface antigens to evaluate the phenotype of CD52 CAR-T cells after infection. Flow cytometry and ELISA were used to evaluate the specific cytotoxicity of CD52 CAR-T cells to CD52-positive cell lines in vitro. Results: ①A pCDH-CD52scFv-CD8α-4-1BB-CD3ζ-GFP expressing plasmid was successfully constructed and used to transduce T cells expressing a novel CD52-targeting CAR. ②On day 6, CD52-positive T cells were almost killed by CD52-targeted CAR-T post lentivirus transduction [CD52 CAR-T (4.48 ± 4.99) %, vs Vector-T (56.58±19.8) %, P=0.011]. ③T cells transduced with the CAR targeting CD52 showed low levels of apoptosis and could be expanded long-term ex vivo. ④The CD52 CAR could promote T cell differentiation into central and effector memory T cells, whereas the proportion of T cells with a CD45RA(+) effector memory phenotype were reduced. ⑤CD52 CAR-T cells could specifically kill CD52-positive HuT78-19t cells but had no killing effect on CD52-negative MOLT4-19t cells. For CD52 CAR-T cells, the percentage of residual of HuT78-19t cells was (2.66±1.60) % at an the E:T ratio of 1∶1 for 24 h, while (56.66±5.74) % of MOLT4-19t cells survived (P<0.001) . ⑥The results of a degranulation experiment confirmed that HuT78-19t cells significantly activated CD52 CAR-T cells but not MOLT4-19t cells[ (57.34±11.25) % vs (13.06± 4.23) %, P<0.001]. ⑦CD52 CAR-T cells released more cytokines when co-cultured with HuT78-19t cells than that of vector-T cells [IFN-γ: (3706±226) pg/ml, P<0.001; TNF-α: (1732±560) pg/ml, P<0.01]. Conclusions: We successfully prepared CD52 CAR-T cells with anti-leukemia effects, which might provide the foundation for further immunotherapy.
CD52 Antigen
;
Cell Line, Tumor
;
Humans
;
Immunotherapy, Adoptive/methods*
;
Lentivirus/genetics*
;
Leukemia
;
Receptors, Antigen, T-Cell
;
Receptors, Chimeric Antigen/genetics*
10.Lymphatic vessels, miRNAs, and CAR T cells in tumor immunology.
Journal of Zhejiang University. Science. B 2020;21(1):1-2
This special feature contains three review articles that summarize recent advances pertaining to tumor immunobiology. Normalization of antitumor immunity through checkpoint inhibitors has achieved significant clinical success and benefited many cancer patients. However, not all cancer patients respond to these treatments, and among the responders, some may develop resistance and others may suffer autoimmunity that requires intervention. Tumor immunotherapy holds promise for further improving the survival of cancer patients, but deeper understanding of immunological networks that regulate anti- and pro-tumor immunity is needed. The review papers collected in this issue cover a few topics that may stimulate future interest in the relevant research field.
Humans
;
Immunotherapy, Adoptive/methods*
;
Lymphatic Vessels/physiology*
;
MicroRNAs/physiology*
;
Neoplasms/therapy*
;
Receptors, Chimeric Antigen/immunology*
;
T-Lymphocytes/immunology*